1083169-01-0 Usage
Uses
Used in Organic Synthesis:
(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)boronic acid is used as a reagent in organic synthesis for its capacity to form reversible covalent bonds with diols and other Lewis bases, facilitating the creation of a variety of complex organic compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)boronic acid is used as a building block for the development of pharmaceuticals. Its unique structure allows it to be incorporated into drug candidates that may have specific therapeutic effects.
Used in Drug Development:
(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)boronic acid is used as a component in the development of new drugs due to its potential to enhance the properties of pharmaceutical compounds, such as their binding affinity or selectivity for biological targets.
Used in Material Science:
Although not explicitly mentioned in the provided materials, given the compound's unique structure and reactivity, it may also find applications in material science for the development of new materials with specific properties, such as improved catalytic activity or sensing capabilities. Further research would be required to confirm these potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1083169-01-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,3,1,6 and 9 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1083169-01:
(9*1)+(8*0)+(7*8)+(6*3)+(5*1)+(4*6)+(3*9)+(2*0)+(1*1)=140
140 % 10 = 0
So 1083169-01-0 is a valid CAS Registry Number.
1083169-01-0Relevant academic research and scientific papers
Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock
Dreas, Agnieszka,Kucwaj-Brysz, Katarzyna,Pyziak, Karolina,Kulesza, Urszula,Wincza, Ewelina,Fabritius, Charles-Henry,Michalik, Kinga,Gabor-Worwa, Ewelina,Go?as, Aniela,Milik, Mariusz,Masiejczyk, Magdalena,Majewska, Eliza,Py?niak, Kazimiera,Wójcik-Trechcińska, Urszula,Sandowska-Markiewicz, Zuzanna,Brzózka, Krzysztof,Ostrowski, Jerzy,Rzymski, Tomasz,Mikula, Michal
supporting information, (2020/12/13)
The mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (MNKs 1/2) and their downstream target eIF4E, play a role in oncogenic transformation, progression and metastasis. These results provided rationale for development of first MNKs inhibitors, currently in clinical trials for cancer treatment. Inhibitors of the MNKs/eIF4E pathway are also proposed as treatment strategy for inflammatory conditions. Here we present results of optimization of indazole-pyridinone derived MNK1/2 inhibitors among which compounds 24 and 26, selective and metabolically stable derivatives. Both compounds decreased levels of eIF4E Ser206 phosphorylation (pSer209-eIF4E) in MOLM16 cell line. When administered in mice compounds 24 and 26 significantly improved survival rates of animals in the endotoxin lethal dose challenge model, with concomitant reduction of proinflammatory cytokine levels – TNFα and IL-6 in serum. Identified MNK1/2 inhibitors represent a novel class of immunomodulatory compounds with a potential for the treatment of inflammatory diseases including sepsis.
